Navigate
X
    QualityStocks
  • 18 years ago

Orexigen Therapeutics, Inc. (NASDAQ: OREX)

Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company, has focused their efforts on the development of pharmaceutical product candidates designed to treat obesity and other central nervous system-related disorders. The company’s lead combination product candidates targeted for obesity include: Contrave®, which is in Phase 3 clinical trials; and Empatic™, which is in the later stages of Phase 2 clinical development. For further information, visit the Company’s web site at www.orexigen.com.

Tags Rodman & Renshaw
Related Post
  1. Quantum BioPharma Ltd. (NASDAQ: QNTM) Pursues a New Path for Better Multiple Sclerosis Treatments

    In the United States alone, close to one million people are living with MS, with…

  2. Why Verbal Skills Aren’t Enough: WRAP’s New Doctrine Aims to Give Officers a Lawful Next Step

    California's SB 230 requires agencies to incorporate de-escalation and alternatives to force into their use-of-force…

  3. Beeline Holdings Inc. (NASDAQ: BLNE) Partners with Loft 100 Studios to Examine the Mortgage Market and New Approaches to Homeownership

    The partnership will focus on the production of a 45-minute “Bizumentary” examining current challenges and…